ACB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aurora Cannabis Inc is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is trading below key resistance with bearish momentum, weak recent earnings quality, and no strong proprietary buy signal. If the investor is impatient and unwilling to wait, this is still not an attractive immediate entry.
ACB is in a weak technical position. The MACD histogram is negative and expanding, indicating downside momentum is still building. RSI at 46.86 is neutral, so there is no oversold bounce signal yet. The moving averages are bearish with SMA_200 > SMA_20 > SMA_5, confirming the longer-term trend remains down. Price at 3.4384 is below the pivot at 3.419 but still under R1 at 3.541, so upside breakout confirmation is lacking. Near-term support sits at 3.296 (S1), with further support at 3.221 (S2).
["Revenue in 2026/Q3 increased 6.79% year over year to 94.19 million, showing top-line growth is still positive.", "Gross margin improved sharply to 5.93, up 69.91% YoY, suggesting some operational efficiency improvement.", "Options positioning shows bullish bias with low put-call ratios.", "No significant insider selling trend and no notable hedge fund accumulation signal."]
["Net income fell 93.63% YoY to 1.82 million in 2026/Q3.", "EPS dropped 94.23% YoY to 0.03, indicating earnings deterioration despite revenue growth.", "MACD remains negative and widening, reinforcing downside momentum.", "Bearish moving average structure signals the stock is still in a downtrend.", "No AI Stock Picker signal and no SwingMax signal today.", "No recent congress trading data or influential buyer activity to support a catalyst.", "News provided does not relate to Aurora Cannabis and offers no direct positive catalyst for ACB."]
Latest quarter: 2026/Q3. Revenue grew 6.79% YoY to 94.19 million, which is constructive, but profitability weakened sharply. Net income declined 93.63% YoY to 1.82 million and EPS fell 94.23% YoY to 0.03. Gross margin improved to 5.93, up 69.91% YoY, but the earnings collapse outweighs the revenue improvement for a long-term buy decision.
Recent analyst rating and price target trend data was not provided. Based on the available Wall Street-style signals, the pros case is limited to modest revenue growth, improved gross margin, and somewhat bullish options positioning. The cons case is stronger: deteriorating earnings, no clear technical reversal, and no supportive insider or institutional buying trend. Overall, Wall Street evidence in the provided data leans cautious rather than bullish.
